<DOC>
	<DOCNO>NCT01362933</DOCNO>
	<brief_summary>Treatment venous thromboembolism cancer patient specific validated trial favor use LMWH ( Low Molecular Weight Heparin ) instead VKA ( Vitamin K Antagonist ) treatment 6 month . International recommendation diffuse option.It necessary evaluate compliance physician treatment measure number patient cancer treat long term use LMWH .</brief_summary>
	<brief_title>National Evaluation Adherence Recommendations Venous Thrombo Embolism Treatment Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<criteria>All patient cancer present clinic , hospital , patient diagnose VTE 6 previous month . VTE symptomatic asymptomatic , locate close central line , type ( DVT , PE , SVT ) Patient already include trial study antithrombotic therapy Patient refuse study Patient 18 and/or competent give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>PE</keyword>
	<keyword>DVT</keyword>
	<keyword>SVT</keyword>
	<keyword>LMWH</keyword>
	<keyword>VKA</keyword>
	<keyword>international Venous Thromboembolism Recommendations</keyword>
</DOC>